Trials / Conditions / Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

12 registered clinical trials studyying Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intra NCT06058663	Mayo Clinic	Phase 1
Terminated	NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma NCT06420349	Mayo Clinic	Phase 1
Active Not Recruiting	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A Co NCT05564403	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangio NCT06178588	University of Kansas Medical Center	Phase 2
Recruiting	Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the T NCT05285358	City of Hope Medical Center	Phase 1
Active Not Recruiting	Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or With NCT04941287	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocar NCT04708067	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for NCT04251715	OHSU Knight Cancer Institute	Phase 2
Active Not Recruiting	Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver NCT04175912	National Cancer Institute (NCI)	Phase 2
Recruiting	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inh NCT03942328	Mayo Clinic	Phase 1 / Phase 2
Completed	Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnos NCT03768414	SWOG Cancer Research Network	Phase 3
Completed	Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be NCT03201458	National Cancer Institute (NCI)	Phase 2